Importance of optimal dosing ≥30 mg/kg/d during deferasirox treatment: 2.7-yr follow-up from the ESCALATOR study in patients with β-thalassaemia
Ali Taher, Mohsen S. Elalfy, Kusai Al Zir, Shahina Daar, Abdullah Al Jefri, Dany Habr, Ulrike Kriemler-Krahn, Ali El-Ali, Bernard Roubert, Amal El-BeshlawyVolume:
87
Year:
2011
Language:
english
Pages:
11
DOI:
10.1111/j.1600-0609.2011.01662.x
File:
PDF, 394 KB
english, 2011